China NMPA Drug Inspection - Xian Lijun Pharmaceutical Co., Ltd - Vitamin C injection

The Ningxia Food and Drug Administration, operating under the National Medical Products Administration (NMPA) framework, conducted a comprehensive regional drug quality sampling inspection, announced on June 9, 2017. Executed according to its '2017 Regional Drug Sampling Inspection Work Plan', the inspection covered 96 batches across 40 different drug varieties. This included 66 batches of 21 chemical drugs and 30 batches of 19 traditional Chinese medicine decoction pieces, involving numerous companies such as Shandong Fangming Pharmaceutical Group, Shanghai Huayuan Pharmaceutical (Ningxia) Shasai Pharmaceutical Co., Ltd., and Pingliang Zhukang Traditional Chinese Medicine Pieces Co., Ltd. The regulatory framework for these evaluations primarily involved adherence to the Chinese Pharmacopoeia (2010 and 2015 editions), various Ministry of Health Drug Standards, National Drug Standards, and specific local chemical drug standards. Crucially, the inspection results indicated full compliance across all sampled drug batches. Therefore, no violations or non-compliant items were identified, and consequently, no specific regulatory actions or remediations were required from any of the manufacturers or distributors involved in this announcement. The report serves to inform the public of the satisfactory quality of drugs sampled within the Ningxia region during this inspection period.